



**FOR IMMEDIATE RELEASE**

## **Affimed to Present at the 26<sup>th</sup> Annual Credit Suisse Healthcare Conference**

*Heidelberg, Germany, November 2, 2017* - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the 26<sup>th</sup> Annual Credit Suisse Healthcare Conference on Wednesday, November 8, 2017 at 12:10 pm MT in Scottsdale, Arizona.

A live webcast of the conference presentation can be accessed through the “Events” section on the “Investors & Media” page of the Affimed website at <http://www.affimed.com/events.php>. A replay of the presentation will be available from Affimed’s website for 30 days following the conference

### **About Affimed N.V.**

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit [www.affimed.com](http://www.affimed.com).

### **Contact:**

Anca Alexandru, Head of Communications, EU IR

Phone: +49 6221 64793341

E-Mail: [a.alexandru@affimed.com](mailto:a.alexandru@affimed.com), [IR@affimed.com](mailto:IR@affimed.com)